Viglita 50
160.00৳ Strip
- Viglita (Vildagliptin) is a potent DPP-4 inhibitor designed for adults with type 2 diabetes mellitus.
- It enhances insulin release and reduces glucagon levels in response to glucose levels, aiding in effective blood sugar control.
- Available in various dosages, Viglita can be used alone or alongside other antidiabetic medications.
- It offers flexibility in treatment options, supporting personalized approaches to managing diabetes effectively.
Brand
|
Square Pharmaceuticals PLC |
|---|---|
Generics
|
Vildagliptin |
Type
|
Tablet |
Indications
Viglita is recommended alongside diet and exercise to enhance glycemic control in patients with type 2 diabetes mellitus, either as monotherapy or in combination with Metformin, a Sulphonylurea, a Thiazolidinedione, or Insulin. This is particularly beneficial when initial treatments do not achieve adequate glycemic control.
Pharmacology
Vildagliptin acts as a dipeptidyl peptidase-4 (DPP-4) inhibitor, which prolongs the action of incretin hormones involved in regulating glucose homeostasis. By increasing active incretin levels, Vildagliptin enhances insulin release and reduces glucagon secretion in a glucose-dependent manner.
Dosage & Administration
The recommended dose of Vildagliptin:
- 50 mg or 100 mg daily as monotherapy.
- 50 mg twice daily (morning and evening) when combined with Metformin or a Thiazolidinedione.
- 50 mg once daily in the morning when combined with a Sulphonylurea.
Vildagliptin can be taken with or without food. No dosage adjustment is necessary for elderly patients or those with mild renal impairment.
Interaction
Viglita shows no significant interactions in pharmacokinetic studies with medications such as pioglitazone, metformin, glibenclamide, and others. However, its glucose-lowering effects may be affected by certain substances like thiazides and corticosteroids.
Contraindications
Vildagliptin is contraindicated in patients:
- With hypersensitivity to the active substance or any excipients.
- Who have moderate to severe renal impairment.
- With hepatic impairment or elevated liver enzymes (ALT or AST >3 times ULN).
- Diagnosed with type 1 diabetes mellitus.
Side Effects
Most adverse reactions to Viglita are mild and transient, with rare cases of hepatic dysfunction reported. Long-term clinical trials have not revealed any additional safety concerns.
Pregnancy & Lactation
Vildagliptin should not be used during pregnancy or lactation.
Precautions & Warnings
Caution is advised for patients aged 75 years and older. Liver function tests (LFTs) should be monitored before starting Vildagliptin and periodically thereafter. Discontinue treatment if liver enzymes remain elevated or if signs of liver dysfunction develop.
Therapeutic Class
Dipeptidyl Peptidase-4 (DPP-4) inhibitor
Storage Conditions
Store below 30°C, protected from light and moisture. Keep out of reach of children.
Reviews
There are no reviews yet.